Generon Corporation (Shanghai) Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Our research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. Our cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China.

Our mission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs.
We employ our proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. We are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. We follow international quality standards for our product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing.

Our products are in various stages of clinical development. F-627, a potential best-in-class recombinant human granulocyte colony-stimulating factor (rhG-CSF) dimer, is in Phase III clinical trials in the US, EU and China to treat chemotherapy-induced neutropenia in cancer patients. F-652, a first-in-class recombinant human interleukin-22, is in Phase IIa clinical trials in the US for the treatment of graft-vs-host disease (GvHD), and acute alcoholic hepatitis. In addition, we have multiple immune oncology bi-specific antibodies in preclinical development ready for clinical development.